Vaccine therapy using rgp 160 in early HIV infection

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1333. doi: 10.1089/aid.1992.8.1333.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Randomized Controlled Trial

MeSH terms

  • CD4-Positive T-Lymphocytes
  • Gene Products, env / immunology
  • Gene Products, env / therapeutic use*
  • HIV Antibodies / biosynthesis
  • HIV Envelope Protein gp160
  • HIV Infections / immunology
  • HIV Infections / therapy*
  • Humans
  • Immunity, Cellular
  • Immunization, Secondary
  • Immunotherapy, Active*
  • Leukocyte Count
  • Protein Precursors / immunology
  • Protein Precursors / therapeutic use*
  • Recombinant Fusion Proteins / immunology
  • Recombinant Fusion Proteins / therapeutic use
  • Vaccines, Synthetic / immunology
  • Vaccines, Synthetic / therapeutic use*

Substances

  • Gene Products, env
  • HIV Antibodies
  • HIV Envelope Protein gp160
  • Protein Precursors
  • Recombinant Fusion Proteins
  • Vaccines, Synthetic